Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S C van der Schoot

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Pharmaceutical Research|January 25, 2007
Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysisS C van der Schoot, B Nuijen, A D R Huitema, et al.
Drug Development and Industrial Pharmacy|July 30, 2008
Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrinJ H Beijnen, S C van der Schoot, B Nuijen, et al.
International Journal of Pharmaceutics|October 3, 2006
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studiesS C van der Schoot, L D Vainchtein, J H Beijnen, et al.
Die Pharmazie|December 17, 2008
Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrinS C van der Schoot, L D Vainchtein, B Nuijen, et al.
Die Pharmazie|October 31, 2006
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346S C Van der Schoot, B Nuijen, P Sood, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Pharmaceutical Research|January 25, 2007
Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysisS C van der Schoot, B Nuijen, A D R Huitema, et al.
Drug Development and Industrial Pharmacy|July 30, 2008
Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrinJ H Beijnen, S C van der Schoot, B Nuijen, et al.
International Journal of Pharmaceutics|October 3, 2006
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studiesS C van der Schoot, L D Vainchtein, J H Beijnen, et al.
Die Pharmazie|December 17, 2008
Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrinS C van der Schoot, L D Vainchtein, B Nuijen, et al.
Die Pharmazie|October 31, 2006
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346S C Van der Schoot, B Nuijen, P Sood, et al.
Pageof 1